Ovarian Cancer, TNBC, SCLC, Other Solid Tumours Clinical Trial
Official title:
A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
| Verified date | June 2023 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is an open-label, multi-centre, Phase Ib study of AZD1775 designed to assess the safety, tolerability, pharmacokinetics, and anti-tumour activity of AZD1775 monotherapy in patients with advanced solid tumours.
| Status | Completed |
| Enrollment | 92 |
| Est. completion date | August 22, 2019 |
| Est. primary completion date | January 25, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 99 Years |
| Eligibility | Inclusion Criteria: 1. Age =18 2. Previous chemotherapy for recurrent or metastatic disease. 3. Measurable disease is required for Part B expansion cohorts according to RECIST v1.1 criteria. 4. Radiation therapy completed at least 7 days prior to start of study treatment and patients must have recovered from any acute adverse effects. 5. ECOG Performance Status (PS) score of 0-1. 6. Baseline laboratory values as follows: 1. ANC =1500/µL 2. Hgb =9 g/dL 3. Platelets =100,000/µL 4. ALT and AST =3 x ULN or =5 x ULN if known hepatic metastases. 5. Serum bilirubin WNL or =1.5 x the ULN in patients with liver metastases; or total bilirubin =3.0 x ULN with direct bilirubin WNL in patients with well documented Gilbert's Syndrome. 6. Serum creatinine =1.5 x the ULN and a calculated creatinine clearance (CrCl) =45 mL/min by the Cockcroft-Gault method. 7. Negative serum or urine pregnancy test within 3 days prior to start of study treatment. 8. Fertile male patients willing to use at least one medically acceptable form of birth control for the duration of the study and for 2 weeks after treatment stops. 9. Predicted life expectancy =12 weeks. Inclusion Criteria Specific for Part A: 1. Histologically or cytologically documented, locally advanced or metastatic solid tumour, excluding lymphoma, for which standard therapy does not exist or has proven ineffective or intolerable. 2. Has agreed to the collection of archival tumour tissue or recent tumour biopsy tissue, it taken for routine clinical purposes at baseline if archival tissue is not available, for molecular biomarker analyses. Inclusion Criteria Specific for Part B: 1. Ovarian cancer defined as a histologically confirmed diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer refractory to standard therapies of for which no standard therapy exists. Confirmed BRCA1 or BRCA2 mutation from a prior test. Patient progressed while receiving and/or following treatment with a PARP-inhibitor for advanced disease (recurrent or metastatic. 2. Ovarian cancer confirmed BRCA wild-type from a prior test. 3. Triple-negative breast cancer (TNBC) defined as histologically confirmed diagnosis of breast cancer and must have received at least 1 chemotherapy-containing regimen for advanced disease (recurrent or metastatic). Tumour must be triple-negative, defined as minimal or no expression of estrogen and progesterone receptors [<10% of cells positive by immunohistochemistry (IHC)], and minimal or no expression of HER2 (IHC staining 0 or 1+ or FISH-). 4. Small-cell lung cancer (SCLC) defined as a histologically confirmed diagnosis of SCLC and must have received at least 1 chemotherapy-containing regimen for advanced disease (recurrent or metastatic). Exclusion Criteria: 1. Any chemotherapy within 3 weeks of the first dose of AZD1775, except hormonal therapy in the refractory cohort. 2. Use of a study drug =21 days or 5 half-lives, whichever is shorter. 3. Major surgical procedures =28 days, or minor procedures =7 days. 4. Grade >1 toxicity from prior therapy (except alopecia or anorexia). 5. CNS disease other than neurologically stable, treated brain metastases. 6. Prescription or non-prescription drugs or other products known to be sensitive to CYP3A4 substrates or CYP3A4 substrates with a narrow therapeutic index, or to be moderate to strong inhibitors/inducers of CYP3A4 which cannot be discontinued two weeks prior to Day 1 of dosing and withheld throughout the study until 2 weeks after the last dose of study drug. 7. NYHA = Class 2. 8. Mean resting corrected QT interval (QTc) =450 msec for males and =470 msec for females. 9. Pregnant or lactating. 10. Serious active infection, or serious underlying medical condition. 12. Presence of other active invasive cancers. 13. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol. |
| Country | Name | City | State |
|---|---|---|---|
| Canada | Research Site | Edmonton | Alberta |
| Canada | Research Site | Toronto | Ontario |
| Canada | Research Site | Vancouver | British Columbia |
| United States | Research Site | Charlotte | North Carolina |
| United States | Research Site | Detroit | Michigan |
| United States | Research Site | Fayetteville | Arkansas |
| United States | Research Site | Fort Myers | Florida |
| United States | Research Site | Greenville | South Carolina |
| United States | Research Site | Houston | Texas |
| United States | Research Site | Indianapolis | Indiana |
| United States | Research Site | Milwaukee | Wisconsin |
| United States | Research Site | Nashville | Tennessee |
| United States | Research Site | Oklahoma City | Oklahoma |
| United States | Research Site | Philadelphia | Pennsylvania |
| United States | Research Site | San Francisco | California |
| United States | Research Site | West Hollywood | California |
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca |
United States, Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and dose-limiting toxicities (DLTs) as a measure of safety and tolerability. | The AZD1775 dose is considered safe and tolerable if = 1 of 6 patients experiences a DLT. | From first dose of study treatment up to last day of Cycle 1 (21 days) | |
| Secondary | Objective Response Rate (ORR) | The proportion of patients achieving a complete or partial tumour response (CR or PR) according to RECIST 1.1 criteria. | Every 6 weeks until treatment discontinuation as defined by RECIST 1.1, projected 12 months. | |
| Secondary | Disease Control Rate (DCR) | The proportion of patients achieving a complete response (CR) or partial response (PR), or stable disease (SD) according to RECIST v1.1 criteria | Every 6 weeks until treatment discontinuation as defined by RECIST 1.1, projected 12 months | |
| Secondary | Duration of Response (DoR) | The time from first documented tumor response until the date of documented progression or death from any cause. | Every 6 weeks until treatment discontinuation as defined by RECIST 1.1, projected 12 months | |
| Secondary | Progression Free Survival (PFS) | Defined as the time from date of first dose of AZD1775 until the date of objective disease progression or death by any cause as defined by RECIST 1.1. | Every 6 weeks until treatment discontinuation as defined by RECIST 1.1, project 12 months. | |
| Secondary | PK profile: Plasma concentrations of AZD1775 and PK parameters (Cmax, C8hr, tmax, AUC, tlast, t½?z) | Blood samples will be collected at various timepoints post-dosing | Pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose of AZD1775 during Cycle 1-Day 1 and Cycle 1-Day3 or Day-10 of the safety lead-in part of study | |
| Secondary | QTc prolongation | ECGs will be obtained at various timepoints | ECGs collected pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose in Cycle 1-Day 1 and on Cycle 1-Day 3 or Day 10. |